$ 50,000

Ind Application Filing [Member] | A L001 License [Member]

Pre-IND Meeting - Completed September 2019

^[1]

$ 65,000

Upon First Dosing of Patient in Clinical Trial [Member] | A L001 License [Member]

IND application filing - Completed June 2021

^[1]

$ 190,000

Upon first dosing of patient in a clinical trial - Completed December 2021

^[1]

$ 500,000

Upon completion of first clinical trial - Completed March 2022

^[1]

$ 1,250,000

Upon first patient treated in a Phase III clinical trial

$ 2,000,000

Upon first patient treated in a Phase III clinical trial

$ 10,000,000

Upon FDA NDA approval

$ 50,000

Upon IND application - Completed January 2022

^[2]

$ 50,000

Upon first dosing of patient in first Phase I clinical trial

$ 500,000

Upon completion of first Phase IIB clinical trial

$ 1,000,000

Upon first patient treated in a Phase III clinical trial

$ 10,000,000

Upon first commercial sale

$ 16,000,000